MARKET

ICAD

ICAD

ICAD US
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.40
-0.08
-0.76%
After Hours: 10.40 0 0.00% 16:00 08/07 EDT
OPEN
10.44
PREV CLOSE
10.48
HIGH
10.54
LOW
10.06
VOLUME
188.72K
TURNOVER
--
52 WEEK HIGH
15.31
52 WEEK LOW
5.50
MARKET CAP
237.68M
P/E (TTM)
-9.3542
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ICAD stock price target is 14.70 with a high estimate of 16.00 and a low estimate of 13.50.

EPS

ICAD News

More
iCAD EPS beats by $0.12, beats on revenue
iCAD (NASDAQ:ICAD): Q2 Non-GAAP EPS of -$0.12; GAAP EPS of -$0.11 beats by $0.12. Revenue of $5.6M (-23.6% Y/Y) beats by $1.37M. Press Release
seekingalpha · 4d ago
icad Q2 EPS $(0.12) Beats $(0.22) Estimate, Sales $5.57M Beat $4.23M Estimate
icad (NASDAQ:ICAD) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.22) by 45.45 percent. This is a 33.33 percent decrease over losses of $(0.09) per share from the same
Benzinga · 4d ago
iCAD Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020
Launched ProFound AI™ Risk Offering After Receiving CE Mark in Europe Recent 50 System Agreement with SimonMed Imaging Highlights Significant Value of ProFound AI SolutionExpert Panel Reviews Compelling Clinical Data on Xoft® Brain IORTConference Call Today a
GlobeNewswire · 4d ago
iCAD to Report Second Quarter 2020 Financial Results on Tuesday, August 4
NASHUA, N.H., July 28, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter and six-mon
GlobeNewswire · 07/28 20:01
iCAD Announces ProFound AI Risk Receives CE Mark In Europe
First and only commercially available clinical decision support tool provides accuratetwo-year breast cancer risk estimation personalized for each woman iCAD unveils new technology and clinical research at major medical
Benzinga · 07/15 12:04
ProFound AI™ Risk Receives CE Mark in Europe
First and only commercially available clinical decision support tool provides accurate two-year breast cancer risk estimation personalized for each woman iCAD unveils new.
GlobeNewswire · 07/15 12:00
Edited Transcript of ICAD earnings conference call or presentation 11-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 07/11 06:54
iCAD Inc (ICAD): Hedge Funds Sticking Around
Insider Monkey · 07/02 21:56

Industry

Advanced Medical Equipment & Technology
+0.47%
Healthcare Equipment & Supplies
+0.49%

Hot Stocks

Symbol
Price
%Change

About ICAD

iCAD, Inc. is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). The Detection segment consists of its advanced image analysis and workflow products, and the Therapy segment consists of its radiation therapy products. The Company sells its products through its direct sales organization, as well as through various original equipment manufacturer partners, distributors and resellers. It develops and markets computer-aided detection (CAD) solutions for digital and film-based mammography systems. Its Axxent SPX Controller includes an optimized skin treatment arm customized for compatibility in confined patient treatment rooms in physician office-based facilities.
More

Webull offers kinds of iCAD Inc stock information, including NASDAQ:ICAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICAD stock methods without spending real money on the virtual paper trading platform.